Company: AZN
Filing Date: 2025-07-29
Form Type: 6-K
Source: 0001104659-25-071432
Chunk: 5

Company: ASTRAZENECA PLC
Filing Date: 2025-07-29
Form: 6-K
Chunk 5
---
rowth in Emerging Markets, generic erosion elsewhere | ​ |
| Others  | ​ |      88 | ​ |      -15 | ​ | -15 | ​ | ●Generic erosion                                       | ​ |

14

R&D progress This section covers R&D events and milestones that occurred between 29 April 2025 and 28 July 2025. A comprehensive view of AstraZeneca's pipeline of medicines in human trials can be found in the latest Clinical Trials Appendix, available on AstraZeneca’s investor relations webpage. The Clinical Trials Appendix includes tables with details of the ongoing clinical trials for AstraZeneca medicines and new molecular entities in the pipeline. Oncology AstraZeneca presented new data across its diverse portfolio of cancer medicines at two major medical congresses since the prior results announcement: the American Society of Clinical Oncology Annual Meeting 2025 and the European Hematology Association Congress 2025. Across the two meetings, more than 100 abstracts were presented featuring 23 approved and potential new medicines including 25 oral presentations. Calquence

| ApprovalEU | ECHOMay 2025                     | ●In combination with bendamustine and rituximab for the treatment of previously untreated mantle cell lymphoma who are not eligible for autologous stem cell transplant.    |
| ApprovalEU | ACE-LY-004May 2025New disclosure | ●For the treatment of relapsed or refractory mantle cell lymphoma not previously treated with a BTK inhibitor.                                                              |
| ApprovalEU | AMPLIFYJune 2025                 | ●Fixed-duration regimen of Calquence in combination with venetoclax, with or without obinutuzumab, for the treatment of previously untreated chronic lymphocytic leukaemia. |

Datroway

| ApprovalUS | TROPION-Lung05,         
 Tropion-Lung01June 2025 | ●For the treatment of locally advanced or metastatic EGFRm NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy. |

Enhertu

| Phase III readout​ | DESTINY-Breast11May 2025  | ●Positive high-level results demonstrated that Enhertu followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pCR rate versus standard-of-care (dose-dense doxorubicin and cyclophosphamide followed by THP) when used in the ne